In order to further verify PI3K/AKT pathway function in cervical cancer cells, the AKT inhibitor LY294002 was adopted to inhibit the phosphorylation level of AKT existing in siha and caski cells, as demonstrated in Figure 6D. Here, AKT1 is linked to cervical cancer.